Home>Media Center>CCCEU News

BGI gets CE mark for SARS-CoV-2 Antigen Detection Kit

bgi.com| Updated: Feb 8, 2021
Share        

BGI Genomics Co. LTD., announces that its SARS-CoV-2 Virus Antigen Detection Kit (colloidal gold method) has been CE marked.

The kit produced by BGI PathoGenesis Pharmaceutical Technology Co. Ltd., a subsidiary of BGI Genomics, can directly detect SARS-CoV-2 specific proteins (i.e. antigens), which can be used for in vitro qualitative detection of COVID-19 in oropharyngeal and nasopharyngeal swab samples.

Fast and efficient detection method play an important role in the prevention of COVID-19 pandemic. Due to its speed and convenience, antigen detection products can be used for rapid auxiliary diagnosis of suspected populations during acute infection and rapid auxiliary investigation of targeted populations, which can better meet the needs of countries for rapid detection and prevention during the pandemic.

Antigen detection should not be used as the sole basis for the diagnostic of novel coronavirus, but should be confirmed by nucleic acid detection in combination with symptoms, and exposure history when necessary.